A selective BCR-ABL inhibitor, imatinib, has been introduced into clinical practice in 2001 and represents a breakthrough in CML therapy [2,3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.